Mutation of the PIK3CA oncogene in human cancers - PubMed (original) (raw)
Review
Mutation of the PIK3CA oncogene in human cancers
B Karakas et al. Br J Cancer. 2006.
Abstract
It is now well established that cancer is a genetic disease and that somatic mutations of oncogenes and tumour suppressor genes are the initiators of the carcinogenic process. The phosphatidylinositol 3-kinase signalling pathway has previously been implicated in tumorigenesis, and evidence over the past year suggests a pivotal role for the phosphatidylinositol 3-kinase catalytic subunit, PIK3CA, in human cancers. In this review, we analyse recent reports describing PIK3CA mutations in a variety of human malignancies, and discuss their possible implications for diagnosis and therapy.
Figures
Figure 1
(A) The main reaction catalysed by PI3K: phosphatidylinositol (PI) 4,5 bisphosphate (PIP2) to phosphatidylinositol (PI) 3,4,5-triphosphate (PIP3). (B) PI3K is activated upon ligand binding to a receptor tyrosine kinase (RTK), which then activates the regulatory subunit (p85) to bind the catalytic p110_α_ subunit. This ultimately triggers various downstream signalling cascades resulting in cell survival, apoptosis, transformation, metastasis, and cell migration. (C) Schematic representation of PIK3CA (p110_α_ catalytic subunit of PI3K) and its functional domains with the most common somatic mutations, E542K, E545K and H1047R within the helical and kinase domains indicated.
Similar articles
- Genetic deregulation of the PIK3CA oncogene in oral cancer.
Murugan AK, Munirajan AK, Tsuchida N. Murugan AK, et al. Cancer Lett. 2013 Sep 28;338(2):193-203. doi: 10.1016/j.canlet.2013.04.005. Epub 2013 Apr 15. Cancer Lett. 2013. PMID: 23597702 Review. - Oncogenic mutations of PIK3CA in human cancers.
Samuels Y, Velculescu VE. Samuels Y, et al. Cell Cycle. 2004 Oct;3(10):1221-4. doi: 10.4161/cc.3.10.1164. Epub 2004 Oct 12. Cell Cycle. 2004. PMID: 15467468 - A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P, Levidou G, Trigka EA, Prekete N, Karlou M, Thymara I, Sakellariou S, Fragkou P, Isaiadis D, Pavlopoulos P, Patsouris E, Saetta AA. Korkolopoulou P, et al. BJU Int. 2012 Dec;110(11 Pt C):E1237-48. doi: 10.1111/j.1464-410X.2012.11569.x. Epub 2012 Oct 29. BJU Int. 2012. PMID: 23107319 - Mouse Models for Exploring the Biological Consequences and Clinical Significance of PIK3CA Mutations.
Mitchell CB, Phillips WA. Mitchell CB, et al. Biomolecules. 2019 Apr 23;9(4):158. doi: 10.3390/biom9040158. Biomolecules. 2019. PMID: 31018529 Free PMC article. Review. - Gene of the month: PIK3CA.
Lai K, Killingsworth MC, Lee CS. Lai K, et al. J Clin Pathol. 2015 Apr;68(4):253-7. doi: 10.1136/jclinpath-2015-202885. Epub 2015 Feb 16. J Clin Pathol. 2015. PMID: 25688137 Review.
Cited by
- Activation of the PI3K/AKT pathway in Merkel cell carcinoma.
Hafner C, Houben R, Baeurle A, Ritter C, Schrama D, Landthaler M, Becker JC. Hafner C, et al. PLoS One. 2012;7(2):e31255. doi: 10.1371/journal.pone.0031255. Epub 2012 Feb 17. PLoS One. 2012. PMID: 22363598 Free PMC article. - Domain landscapes of somatic mutations in cancer.
Nehrt NL, Peterson TA, Park D, Kann MG. Nehrt NL, et al. BMC Genomics. 2012 Jun 18;13 Suppl 4(Suppl 4):S9. doi: 10.1186/1471-2164-13-S4-S9. BMC Genomics. 2012. PMID: 22759657 Free PMC article. - BRCA1 protein levels and PIK3CA mutations as predictive biomarkers for response to neoadjuvant chemotherapy in locally advanced breast cancer: An exploratory analysis.
Hilton J, Weberpals J, Lorimer I, Amin S, Islam S, Pelletier L, Daneshmand M, Hanson J, Nabavi M, Parolin D, Mallick R, Verma S. Hilton J, et al. Oncol Lett. 2012 Jul;4(1):141-145. doi: 10.3892/ol.2012.697. Epub 2012 Apr 26. Oncol Lett. 2012. PMID: 22807977 Free PMC article. - Mutational analysis of uterine cervical cancer that survived multiple rounds of radiotherapy.
Nuryadi E, Sasaki Y, Hagiwara Y, Permata TBM, Sato H, Komatsu S, Yoshimoto Y, Murata K, Ando K, Kubo N, Okonogi N, Takakusagi Y, Adachi A, Iwanaga M, Tsuchida K, Tamaki T, Noda SE, Hirota Y, Shibata A, Ohno T, Tokino T, Oike T, Nakano T. Nuryadi E, et al. Oncotarget. 2018 Aug 24;9(66):32642-32652. doi: 10.18632/oncotarget.25982. eCollection 2018 Aug 24. Oncotarget. 2018. PMID: 30220971 Free PMC article. - A Rare Pathological Phenotype of Endometrioid Serous and Clear-Cell Ovarian Cancer with PIK3CA Mutations in Relation to The Excellent Response of Alpelisib.
Bayram E, Khatib G, Guney B, Kilicbagir E, Gulec HR, Boga I, Paydas S. Bayram E, et al. Genes (Basel). 2023 Aug 16;14(8):1632. doi: 10.3390/genes14081632. Genes (Basel). 2023. PMID: 37628682 Free PMC article.
References
- Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, Konishi H, Karakas B, Blair BG, Lin C, Peters AB, Velculescu VE, Park BH (2004) The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 3: 772–775 - PubMed
- Broderick DK, Di C, Parrett TJ, Samuels YR, Cummins JM, McLendon RE, Fults DW, Velculescu VE, Bigner DD, Yan H (2004) Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res 64: 5048–5050 - PubMed
- Campbell IG, Russell SE, Choong DYH, Montgomery KG, Ciavarella ML, Hooi CSF, Cristiano BE, Pearson RB, Phillips WA (2004) Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 64: 7678–7681 - PubMed
- Cantley LC (2002) The phosphoinositide 3-kinase pathway. Science 296: 1655–1657 - PubMed
- Cantley LC, Auger KR, Carpenter C, Duckworth B, Graziani A, Kapeller R, Soltoff S (1991) Oncogenes and signal transduction. Cell 64: 281–302 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous